Table 2A.

AACR GENIE lung adenocarcinoma co-occurring mutations

All lung adenocarcinomas (n = 5,060 samples)
TP53 mutationa2,333 (46.1%)
KRAS mutationb1,649 (32.6%)
STK11 mutationc665 (13.4%)
MutationsdAll TP53 mutations n = 1,667 samples (1,750 missense mutations)Lung-enriched TP53 mutations (V157, R158, A159) n = 146 samples (147 missense mutations)
TP53 without KRAS or STK111,100 (66.0%)86 (58.9%)
TP53 and KRAS434 (26.0%)52 (35.6%)
TP53 and STK11185 (11.1%)12 (8.2%)
TP53, KRAS, and STK1152 (3.1%)4 (2.7%)
  • aTP53 mutations include 2,325 samples with mutations, 3 samples with fusions, and 5 samples with multiple alterations.

  • bKRAS mutations include 1,625 samples with mutations and 24 samples with multiple alterations.

  • cSTK11 mutations include 652 samples with mutations, 12 samples with fusions, and 1 sample with multiple alterations.

  • Amplifications and deep deletions are excluded.

  • dFrequency is represented in percent of samples with missense mutations out of total number of samples with TP53 missense mutations.